{
    "Trade/Device Name(s)": [
        "CORA\u00ae (Coagulation Resonance Analysis) System",
        "CORA Hemostasis System",
        "CORA Citrated Multichannel Cartridge",
        "CORA Hemostasis System - Abnormal Wet Quality Control (WQC) Material"
    ],
    "Submitter Information": "Coramed Technologies, LLC",
    "510(k) Number": "K150041",
    "Predicate Device Reference 510(k) Number(s)": [
        "K002177"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JPA"
    ],
    "Summary Letter Date": "May 21, 2015",
    "Summary Letter Received Date": "May 22, 2015",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.5425"
    ],
    "Regulation Name(s)": [
        "Multipurpose system for in vitro coagulation studies"
    ],
    "Analyte Class(es)": [
        "coagulation",
        "hematology"
    ],
    "Analyte(s)": [
        "Clotting Time (R)",
        "Speed of Clot Formation (K)",
        "Alpha angle",
        "Maximum Clot Strength (MA)",
        "Estimated Functional Fibrinogen Level (FLEV)",
        "Heparin effect"
    ],
    "Specimen Type(s)": [
        "Venous whole blood",
        "Abnormal Wet Quality Control (WQC) material"
    ],
    "Specimen Container(s)": [
        "3.2% sodium citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "CORA System four-channel diagnostic analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Optical resonance frequency measurement",
        "Microfluidics",
        "Disposable cartridge-based analysis"
    ],
    "Methodologies": [
        "Semi-quantitative in vitro coagulation analysis",
        "Functional hemostasis testing"
    ],
    "Submission Type(s)": [
        "System",
        "Cartridge",
        "Reagent",
        "Quality control material",
        "Analyzer"
    ],
    "Document Summary": "FDA 510(k) summary for CORA (Coagulation Resonance Analysis) System for whole blood hemostasis analysis using optical resonance and dried-in cartridge reagents",
    "Indications for Use Summary": "Intended for in vitro diagnostic evaluation of adult patient blood hemostasis properties, recording kinetic changes in 3.2% citrated whole blood for assessment of hemorrhage or thrombosis conditions before, during, and after procedures.",
    "fda_folder": "Hematology"
}